Despite the global challenges of Covid-19, the EYE Partnership was able to adapt in effective and innovative ways, maintaining delivery of the EYE strategy throughout 2020.

Last year, about **48 million people** were protected against yellow fever in **Africa and the Americas** by mass vaccination campaigns*.

**Our achievements:**

**Global engagement & coordination**

- Development of Decision-making Principles and Standard Operating Procedures to inform global vaccine allocation for preventive mass vaccination (PMV). For more information, click here.
- Gavi applications from 4 countries endorsed by the Independent Review Committee (IRC):
  - **Sudan**: Catch-up campaign aiming to protect > 5.5 million children in 2021.
  - **Uganda**: Introduction into routine immunization (RI) in 2021 and nationwide preventive mass vaccination campaigns (PMVCs) in 2022-2024.
  - **Nigeria**: PMVCs planned for 2021-2022.
  - **Republic of Congo**: PMVCs planned for 2021.
- Successful leveraging of the EYE partnership to procure critical PPE, allowing continuation of vaccination campaigns.
- Virtual annual EYE partners’ meeting, with over 215 participants from 44 countries, on 4 continents.

**Risk analysis & surveillance**

- An updated surveillance standard, with renewed emphasis on detailed clinical, epidemiological and vaccination history. Available here.
- Pilot subnational risk analysis tool used to guide PMVC phasing to support Uganda’s Gavi application.

**Laboratory diagnostics**

- Endorsement of Centre Pasteur du Cameroun (CPC) as the third yellow fever regional reference laboratory (RRL) in Africa.
- 20 high-risk countries in Africa approved for Gavi yellow fever diagnostic procurement support.
- EYE.ops facilitated shipments of over 1000 samples from 13 countries.
- Advances in the external quality assessment (EQA) programme through molecular and serology diagnostic assay evaluation.
- 34 countries participated in the African regional yellow fever surveillance, data management and laboratory workshop held in Uganda. This included regional and global partners.

* The numbers for Nigeria are preliminary.
** The disruptive impact of COVID-19 on routine immunization service delivery is not yet quantified. There may be fewer children vaccinated than initial estimates.
The full EYE Strategy 2017 to 2026 can be found [here](link). Further information on yellow fever can be found [here](link).

A big thank you to all our partners and implementing countries for enabling our 2020 milestones.